Crossroads of pain and addiction

Pain Medicine

Volumn 11, Issue 12, 2010, Pages 1803-1818

  Bailey, John A ^a   Hurley, Robert W ^a   Gold, Mark S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Addiction; Chronic Pain; Drug Abuse; Pain Training Programs

Indexed keywords

HYDROCODONE; OPIATE DERIVATIVE; OXYCODONE;

ARTICLE; CHRONIC PAIN; COMORBIDITY; DRUG ABUSE; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; HUMAN; MEDICAL EDUCATION; MEDICAL SPECIALIST; NEUROBIOLOGY; NONHUMAN; OPIATE ADDICTION; RISK BENEFIT ANALYSIS;

EID: 78650099644     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2010.00982.x     Document Type: Article

References (148)

1. Isaacson J, Fleming M, Kraus M. A national survey of training in substance use disorders in residency programs. J Stud Alcohol 2000;61(6):912-5.
2. Miller N, Sheppard L, Colenda C. Why physicians are unprepared to treat patients who have alcohol and drug-related disorders. Acad Med 2001;76(5):410-8.
3. Flugsrud-Breckenridge M, Gervitz C, Paul D. Medications of abuse in pain management. Curr Opin Anesthesiol 2007;20(4):320-1.
4. Polydorou S, Gunderson E, Levin F. Training physicians to treat substance use disorders. Curr Psychiatry Rep 2008;10:399-404.
5. Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003;289(18):2370-8.
6. Martell B, O'Connor P, Kerns R. Systemic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146(2):116-7.
7. Savage S, Schofferman J. Pain in the addicted patient. In: Principles of Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine; 1994:1406-6.
8. Compton P, Charuvastra V, Ling W. Pain intolerance in opioid-maintained former opiate addicts. Drug Alcohol Depend 2001;63:139-46.
9. Compton MA. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. J Pain Symptom Manage 1994;9:462-73.
10. Modesto-Lowe V, Johnson K, Petry N. Pain management in patients with substance abuse: Treatment challenges for pain and addiction specialists. Am J Addict 2007;16:424-5.
11. Warfield C, Bajwa Z. Principles & Practice of Pain Medicine: Second Edition. New York. McGraw-Hill Professional; 2004:58.
12. Doweiko H. Concepts of Chemical Dependency, 7th edition. Pacific Grove, CA: Brooks Cole; 2008:41.
13. Jung B, Reidenberg M. Physicians being deceived. Pain Med 2007;8(5):433.
14. Grant B, Stinson F, Dawson D. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders. Arch Gen Psychiatry 2004;(61):807-16.
15. Regier D, Farmer M, Rae D, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990;264:2511-8.
16. Wasan A, Wootton J, Jamison R. Dealing with difficult patients in your pain practice. Reg Anesth Pain Med 2005;30(2):184-92.
17. Caravati E, Grey T, Nangle B. Increase in poisoning deaths caused by non-illicit drugs-Utah, 1991-2003. MMWR Morb Mortal Wkly Rep 2005;54(2):33-3.
18. Courtwright D. Dark Paradise: A History of Opiate Addiction in America. Enlarged Edition. Cambridge, MA: Harvard University Press; May 31, 2001.
19. Drug habits. JAMA 2003;290(8):2492.
20. Fishbain D, Cole B, Lewis J, Rosomoff H. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? a structured evidence-based review. Pain Med 2008;9(4):444-5.
21. Porter H, Jick H. Addiction rare in patients treated with narcotics (letter). New Engl J Med 1980;302:123.
22. Portenoy R, Foley K. Chronic use of opioid analgesia in nonmalignant pain: Report of 38 cases. Pain 1986;25(2):171-86.
23. Mendelson JH, Meyer RE, Ellingboe J, Mirin SM, McDougle M. Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther 1975;195:296-302.
24. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3:377-84.
25. Fishbain D, Rosomoff H, Rosomoff R. Drug abuse, dependence and addiction in chronic pain patients. Clin J Pain 1992;8:77-85.
26. Bailey J, Teitelbaum S, Gold M. Addiction: An occupational hazard in anesthesiology. Paradigm 2009;21:22.
27. Dackis C, Gold M. Addictiveness of central stimulants. Adv Alcohol Sub Abuse 1990:9-25.
28. Bozarth M, Wise R. Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 1984;224(4648):516-7.
29. Khazaal Y. Mania after venlafaxine withdrawal in a patient with generalized anxiety disorder. Ann Pharmacother 2007;41:359-60.
30. Zajecka J, Tracy K, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry 1997;58(7):291-7.
31. Savage S, Joranson D, Covington E, et al. Definitions related to the medical use of opioids: Evolution towards universal agreement. J Pain Symptom Manage 2003;26:655-67.
32. Gawin F. Cocaine addiction: Psychology and neurophysiology. Science 1991;251(5001):1580-6.
33. Quote by Logan D. MD. Addiction medicine specialist university of Florida Lecture. Oct 27, 2009.
34. Ballantyne J. Opioid therapy: Is it appropriate in patients with noncancer pain? An evidence-based look at the issue. Am Soc Anesth Rev 2006;3:34.
35. Gardner E. What we have learned about addiction from animal models of drug self-administration. Am J Addict 2000;9:285-313.
36. Gould E, Tanapat P, McEwen B. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA 1998;95:3168-71.
37. Piazza P, LeMoal M. Stress as a factor in addiction. In: Graham A, Schultz T, Wilford B, eds. Principles of Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine; 1998:83-93.
38. Bulik C, Prescott C, Kendler K. Features of childhood sexual abuse and the development of psychiatric and substance use disorders. Br J Psychiatry 2001;179:444-9.
39. Kendler K, Bulik C, Silberg J, et al. Childhood sexual abuse and adult psychiatric and substance use disorders in women: an epidemiological and cotwin control analysis. Arch Gen Psychiatry 2000;57:953-9.
40. Brady K, Sinha R. Co-occurring mental and substance use disorders: The neurobiological effects of chronic stress. Am J Psychiatry 2005;162:1483-93.
41. Sapolsky R. Why stress is bad for your brain. Science 1996;273(suppl 5276):749-50.
42. Schmahl C, Berne K, Krause A, et al. Hippocampus and amygdala volumes in patients with borderline personality disorder with orwithout posttraumatic stress disorder. J Psychiatry Neurosci 2009;34(suppl 4):289-95.
43. Southwick S, Krystal J, Morgan C. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993;50:266-74.
44. Bremner J, Licinio J, Darnell A. Elevated CSF corticotrophin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997;154(suppl 5):624-9.
45. Gracely R, Petzke F, Wolf J. Functional magnetic resonance imaging of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46:1333-43.
46. Koenigs M, Grafman J. Post traumatic stress disorder: the role of the medial prefrontal cortex and amygdale. Neuroscientst 2009;(suppl 6683):373-7.
47. Segman R, Cooper-Kazaz R, Macciardi F, et al. Association between the dopamine transporter gene and posttraumatic stress disorder. Mol Psychiatry 2002;7(suppl 8):903-5.
48. Canive J, Lewine J, Orrison W. MRI reveals gross structural abnormalities in PTSD. Ann NY Acad Sci 1997;821:512-5.
49. Hakamata Y, Matsuoka Y, Inagaki M, et al. Structure of orbitofrontal cortex and its longitudinal course in cancer-related posttraumatic stress disorder. Neurosci Res 2007;59(4):383-9.
50. Dalley J, Fryer T, Brichard L. Nucleus accumbenns D2/3 recepters predict trait impulsivity and cocaine reinforcement. Science 2007;315:1267-70.
51. DuPont R, Gold M. Comorbidity and "self-medication". J Addict Dis 2007;26(suppl 1):13-23.
52. Agrawal A, Grant J, Waldron M, Duncan A, Scherrer J. Risk for initiation of substance use as a function of age of onset of cigarette, alcohol and cannabis use: Findings in a Midwestern female twin cohort. Prev Med 2006;43(2):125-8.
53. Singh M, McGregor J, Mallet P. Perinatal exposure to 9-tetrahydrocannabinol alters heroin-induced place conditioning and fosimmunoreactivity. Neuropsychopharmacology 2006;3:58.
54. Hurd Y, Ellgren M, Spano S. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 2006;32:607.
55. Gardner E. Pain management and the so called risk of addiction: A neurobiological perspective. In: Pain and Chemical Dependency. New York: New York University Press; 2008:432.
56. Ronald T, Libby R. Treating doctors as drug dealers. The DEA's War on Prescription Painkillers. 2005. Available from (accessed September 1, 2009).
57. Hohenstein K. Just what the doctor ordered: The Harrison Anti-Narcotic Act, the Supreme Court, and the federal regulation of medical practice, 1915-1919. J Supreme Court History 2001;26(3):23.
58. Courtwright DT. The controlled substances act: How a "big tent" reform became a punitive law. Drug Alcohol Depend 2004;76(1):9.
59. Prescription opioid-related deaths increased 114% from 2001 to 2005, treatment admissions up 74% in similar period; young adults hardest hit. Available from (accessed October 1, 2009).
60. Passik SD, Kirsh KL. Fear and loathing in the pain clinic. Pain Med 2006;7(4):363-4.
61. Goldenbaum D, Christopher M, Rollin M, Gallagher R, Fishman S. Physicians charged with opioid analgesic-prescribing offenses. Pain Med 2008;9(6):737-47.
62. Model Policy for the Use of Controlled. Substances for the Treatment of Pain Federation of State Medical Boards of the United States. 2004; Available from (accessed September 15, 2009).
63. The Florida Boards of Medicine and Osteopathic Medicine are conducting rulemaking pursuant to SB462. This Available from (accessed October 15, 2009).
64. Devulder J, Richarz U, Nataraja S. Impact of long-term use of opioids on quality of life in patients with chronic nonmalignant pain. Curr Med Res Opin 2005;21:1555-68.
65. Ziegler S, Lovrich N. Pain relief, prescription drugs, and prosecution: A four-state survey of chief prosecutors. J Law Med Ethics 2003;31(1):75-100.
66. Weaver M, Schnoll S. Addiction issues in prescribing opioids for chronic nonmalignant pain. J Addict Med 2007;1(1):2.
67. Kelley A, Berridge K. The neuroscience of natural rewards: Relevance to addictive drugs. J Neurosci 2002;22(suppl 9):3306-11.
68. Gardner E. The neurobiology and genetics of addiction: Implications of the reward deficiency syndrome for therapeutic strategies in chemical dependency. In: Elster J, ed. Addiction: Entries and Exits. New York: Russell Sage Foundation; 1999:57-120.
69. Kalivas P, Volkow N. The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry 2005;162:1403-13.
70. Bruijnzeel A, Repetto M, Gold M. Neurobiological mechanisms in addictive and psychiatric disorders. Psychiatr Clin North Am 2004;27:661.
71. Comings D, Blum K. Reward deficiency syndrome: Genetic aspects of behavioral disorders. Prog Brain Res 2000;126:325-41.
72. Blum K, Chen A, Chen T, et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): A commentary. Theor Biol Med Model 2008;5:24.
73. Koob G. Neuroadaptive mechanisms of addiction: Studies on the extended amygdala. Eur Neuropsychopharmacol 2003;13:6.
74. Porrino L, Lyons D, Smith H, Daunais J, Nader M. Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. J Neurosci 2004;24(14):4560-1.
75. Koob G, Le Moal M. Plasticity of reward neurocircuitry and the "dark side" of addiction. Nat Neurosci 2005;8(11):1442-4.
76. Dackis C, O'Brien C. Neurobiology of addiction: Treatment and public policy ramifications. Nat Neurosci 2005;8(11):1434.
77. Institute of drug abuse, principles of drug addiction treatment. Available from (accessed on November 1, 2008).
78. Humphreys K, Wing S, McCarty D, et al. Self-help organizations for alcohol and drug problems: Toward evidence-based practice and policy. J Subst Abuse Treat 2004;26(3):151-8.
79. Chappel J, DuPont R. Twelve-step and mutual-help programs for addictive disorders. Psychiatr Clin North Am 1999;22(2):425-46.
80. Institute of drug abuse, principles of drug addiction treatment. Available from (accessed on September 1, 2009).
81. Compton W, Volkow N. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83S:S4-7.
82. Samaha A, Robinson T. Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 2005;26(2):82-7.
83. Becerra L, Breiter H, Wise R, et al. Reward circuitry activation by noxious thermal stimulus. Neuron 2001;32:927-46.
84. Sell L, Morris J, Bearn J, et al. Activation of reward circuitry in human opiate addicts. Eur J Neurosci 1999;11:1042-8.
85. Akbik H, Butler S, Budman S, Fernandez K. Validation and clinical application of the screener and opioid assessment for patients with pain. J Pain Symptom Manage 2006;32:287-93.
86. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med 2005;6:432-42.
87. Adams L, Gatchel R, Robinson R, et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage 2004;27:440-59.
88. Compton P, Darakjian D, Miotto K. Screening for addiction in patients with chronic pain and "problematic" substance use: Evaluation of a pilot assessment tool. J Pain Symptom Manage 1998;16(6):355-63.
89. Kahan M, Srivastava A, Wilson L, et al. Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician 2006;52:1081-7.
90. Savage S. Section editors: Jamison, Robert N. Ph.D. Assessment for addiction in pain-treatment settings. Clin J Pain 2002;18:S28-S38.
91. Turk D, Swanson K, Gatchel R. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008;24:497-508.
92. Michna E, Ross E, Hynes W, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004;28(3):250-8.
93. Simoni-Wastila L, Ritter G, Strickler G. Gender and other factors associated with the nonmedical use of abusable prescription drugs. Subst Use Misuse 2004;39:1-23.
94. Sullivan M, Edlund M, Steffick D, et al. Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005;119:95-103.
95. Young S. Balancing clinical and risk management considerations for chronic pain patients on opioid therapy. Available from (accessed October 1, 2009).
96. Friedman R, Li V, Mehrotra D. Treating pain patients at risk: evaluationof a screening tool in opioid-treated pain patients with and without addiction. Pain Med 2003;4(2):182-5.
97. Chakroun N, Doron J, Swendsen J. Substance use, affective problems and personality traits: test of two association models. Encephale 2004;30(6):564-9.
98. Atluri S, Sudarshan G. Screening tool for opioid abuse development of a screening tool to detect the risk of inappropriate prescription opioid use in patients with chronic pain. Pain Physician 2004;7:333-8.
99. Miotto M, Comptom P, Ling W, et al. Diagnostic addictive disease in chronic pain patients. Psychosomatics 1996;3:223-35.
100. Atluri SL, Sudarshan G. Development of a screening tool to detect the risk of inappropriate prescription opioid use in patients with chronic pain. Pain Physician 2004;7:333-8.
101. Kirsh K, Whitcomb L, Donaghy K, Passik S. Abuse and addiction issues in medically ill patients with pain: Attempts at clarification of terms and empirical study. Clin J Pain Issue 2002:18(4):S52-60.
102. Atluri S, Sudarshan G. A screening tool to determine the risk of prescription opioid abuse among patients with nonmalignant pain. Pain Physician 2002;5(4):447-8.
103. Trescot A, Boswell M, Sairam A. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-40.
104. Alcoholics Anonymous World Services. Alcoholics Anonymous, 4 edition. New York: Author; 2001.
105. Francis H, Bill W. A biography of alcoholics anonymous cofounder Bill Wilson (Paperback) St. Martin's Griffin. October 12, 2001. New York City.
106. Weaver M, Schnoll S. Abuse liability in opioid therapy for pain treatment in patients with an addiction history. Clin J Pain 2002;18:S61-9.
107. Markel H. Treatment for addiction meets barriers in the doctor's office. 2003 NY Times. Available from (accessed October 3, 2009).
108. Alcoholics Anonymous World Services. The AA Member: Medications and Other Drugs (pamphlet). General Service Office, Box 459, Grand Central Station, New York, NY 10163.
109. NIDA Infofacts: Treatment Approaches for Drug Addiction. Available from (accessed April 28, 2010).
110. Gorski T, Miller M. Staying Sober-A Guide for Relapse Prevention. Independence. Missouri: Herald House/Independence Press; 1986.
111. Voltaire-Carlsson A, Hiltunen A, Koechling U, Borg S. Effects of long-term abstinence on psychological functioning: a prospective longitudinal analysis comparing alcohol-dependent patients and healthy volunteers. Alcohol 1996;13(5):415-21.
112. Watanabe K, Ogihara-Hashizume A, Kobayashi Y, Mitsushio H, Komiyama T. Impaired sleep during the post-alcohol withdrawal period in alcoholic patients. Addict Biol 2001;6(2):163-9.
113. Reeves R, Brister J. Additional evidence of the abuse potential of quetiapine. South Med J 2007;100(8):834-6.
114. Gonzalez L, Gatch M, Forster M, Dillon G. Abuse potential of Soma®: the GABAA receptor as a target. J Pharmacol Exp Ther 2009;329:827-37.
115. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: Preclinical, clinical, and postmarketing surveillance-A review of abuse liability issues. Acad Clin Psychiatry 2004;16(2):101-9.
116. Svetlov S, Kobeissy F, Gold M. Performance enhancing, nonprescription use of Ritalin: A comparison with amphetamines and cocaine. J Addict Dis 2007;26(4):1-6.
117. Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid induced sedation. Pain Med 2003;4(2):135-40.
118. Heit H. The truth about pain management: The difference between a pain patient and an addicted patient. Eur J Pain 2001;5(suppl A):27-9.
119. Reeves M, Ginifer C. Fatal intravenous misuse of transdermal fent. Med J Aust 2002;177:552-4.
120. Kaiko R, Benziger D, Fitzmartin R, et al. pharmacokinetic-pharmicodynamic relationships of controlled release oxycodone. Clin Pharmacol Ther 1996;59:52-61.
121. Compton W, Volcow N. Major increases in opioid analgesic abuse in the us concerns and stratagies. Drug Alcohol Depend 2006;81:103-7.
122. Walsh S, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003;70:S13-27.
123. Mallinoff H, Barkin R, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther 2005;12(5):379-84.
124. Suboxone Product Information. Available from (accessed October 10, 2009).
125. Heit H, Covington E, Good P. Dear DEA. Pain Med 2004;5(3):303-8.
126. Dupont R, Goldberger B, Gold M. Clinical and legal considerations in drug testing. In: Principles of Addiction Medicine, 4th edition. Baltimore: Lippincott Williams and Wilkins; 2009;1502.
127. Reisfield G, Bertholf R, Barkin R, Webb F, Wilson G. Urine drug test interpretation: what do physicians know? J Opioid Manag 2007;3:80-6.
128. Drug Testing. Available from (accessed October 6, 2010).
129. Jaffee W, Trucco E, Teter C, Levy S, Weiss R. Focus on alcohol and drug abuse: ensuring validity in urine drug testing. Psychiatr Serv 2008;59(2):140-2.
130. DuPont R, Brethen P, Newel R. Drug Testing in Treatment Settings: Guidelines for Effective Use. Minnesota: Hazelden Professional Library; 2005.
131. Hull M, Bierer M, Griggs D. Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay. J Anal Toxicol 2008;32(7):516-21.
132. Nafziger A, Bertino J. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain 2009;25(1):73-9.
133. Reisfield G, Goldberger B, Bertholf R. "False-positive" and "false-negative" test results in clinical urine drug testing. Bioanalysis 2009;1(5):937-47.
134. Thevis M, Opfermann G, Schanzer W. Urinary concentrations of morphine and codeine after consumption of poppy seeds. J Anal Toxicol 2003;27:53-6.
135. SAMHSA, HHS Mandatory Guidelines (Effective 11.1.2004) (Accessed October 6, 2010).
136. Freye E. Opioids in Medicine: A Comprehensive Review on the Mode of Action and the Use of Analgesics in Different Clinical Pain States, 1st edition. New Mexico: Springer; April 28, 2008:420-40.
137. Firstlab. Ethyl Glucuronide. Available from (accessed October 2, 2009).
138. Firstlab. Firstlab report, EtG and EtS: Ethanol Biomarkers. Available from (accessed October 3, 2009).
139. Kintz P. Analytical and Practical Aspects of Drug Testing in Air. Boca Raton, FL: CRC Press; 2006:28.
140. Paterson S, Cordero R. Comparison of the various opiate alkaloid contaminants and their metabolites found in illicit heroin with 6-monoacetyl morphine as indicators of heroin ingestion. J Anal Toxicol 2006;30(4):267-73.
141. Musshoffa F, Drievera F, Lachenmeiera K, et al. Results of hair analyses for drugs of abuse and comparison with self-reports and urine tests. Forensic Sci Int 2006;156:118.
142. Fishman S, Bandman T, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage 1999;18:27-37.
143. Passik S, Kirsh K. Managing pain in patients with aberrant drug-taking behaviors. J Support Oncol 2005;3:83-6.
144. American Academy of Pain Medicine. Clinical resources: Controlled substances sample agreement. Available from (accessed October 5, 2009).
145. Chou R, Fanciullo G, Fine P, Adler J. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30.
146. Center for Drug Free Living, FAQ's. Available from (accessed September 3, 2009).
147. Manchikanti L, Manchukonda R, Damron K, et al. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician 2006;9:57-60.
148. Institute of Drug Abuse, Principles of Drug Addiction Treatment. Available from (accessed August 19, 2009).